ANKMJ

Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

EndNote Style
Index
Review
Concerns about vaccines: ingredients and side effects
Vaccines are among the most effective public health interventions; however, concerns regarding their components and potential adverse effects continue to contribute to vaccine hesitancy. This narrative review aims to critically evaluate the current scientific evidence regarding vaccine ingredients and their alleged side effects. A narrative literature review was conducted using PubMed and Scopus databases. Studies published in English and Turkish over the past 15 years were prioritized, with emphasis on systematic reviews, meta-analyses, and reports from international health authorities (WHO, CDC, EMA). High-quality evidence indicates that commonly discussed vaccine components such as thimerosal, aluminum adjuvants, and formaldehyde are present in quantities that are not associated with clinically significant harm. No causal relationship has been demonstrated between vaccines and autism spectrum disorder. Some hypotheses, such as autoimmune/inflammatory syndrome induced by adjuvants (ASIA), remain controversial and lack robust clinical validation. The current body of scientific evidence strongly supports the safety of vaccines. Misinterpretation of low-quality studies and misinformation contribute significantly to public concerns. Strengthening evidence-based communication is essential to reduce vaccine hesitancy.


1. World Health Organization. Global Vaccine Safety Blueprint 2.0 (2021-2030). World Health Organization; 2021.
2. MacDonald NE. SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. <em>Vaccine</em>. 2015; 33(34):4161-4164. doi:<a href="https://doi.org/10.1016/j.vaccine.2015.04.036">10.1016/j.vaccine.2015.04.036</a>
3. Kesselheim AS, Grady D, Zettler PJ, et al. An overview of vaccine development, approval, and regulation, with implications for COVID-19. <em>Health Aff (Millwood)</em>. 2021;40(1):25-32. doi:<a href="https://doi.org/10.1377/hlthaff.2020.01665">10.1377/hlthaff.2020.01665</a>
4. Centers for Disease Control and Prevention. Vaccine Safety Basics. Centers for Disease Control and Prevention; 2022.
5. Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. <em>Vaccine</em>. 2014;32(19):2150-2159. doi:<a href="https://doi.org/10.1016/j.vaccine.2014.01.081">10.1016/j.vaccine.2014.01.081</a>
6. Pichichero ME, Gentile A, Giglio N, et al.Mercury levels in newborns and infants after receipt of thimerosal-containingvaccines. <em>Pediatrics</em>. 2008;121(2):e208-e214. doi:<a href="https://doi.org/10.1542/peds.2007-1692">10.1542/peds.2007-1692</a>
7. Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. <em>Vaccine</em>. 2014;32(29):3623-3629. doi:<a href="https://doi.org/10.1016/j.vaccine.2014.04.085">10.1016/j.vaccine.2014.04.085</a>
8. Hviid A, Hansen JV, Frisch M, Melbye M. Measles, mumps, rubella vaccination and autism: a nationwide cohort study. <em>Ann Intern Med</em>. 2019;170(8):513-520. doi:<a href="https://doi.org/10.7326/M18-2101">10.7326/M18-2101</a>
9. World Health Organization. Mercury and Health Care: Policy Paper. World Health Organization; 2005.
10. Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. <em>Vaccine</em>. 2011;29(51):9538-9543. doi:<a href="https://doi.org/10.1016/j.vaccine.2011.09.124">10.1016/j.vaccine.2011.09.124</a>
11. European Medicines Agency. Aluminium-Containing Vaccines: Benefit-Risk Assessment Report. European Medicines Agency; 2020.
12. Keith LS, Jones DE, Chou CH. Aluminum toxicokinetics regarding infant vaccine exposure: an updated review. <em>Toxicol Rep</em>. 2023;10:1053-1062. doi:<a href="https://doi.org/10.1016/j.toxrep.2023.05.012">10.1016/j.toxrep.2023.05.012</a>
13. Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012.
14. McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. <em>J Allergy Clin Immunol</em>. 2018;141(2):463-472. doi:<a href="https://doi.org/10.1016/j.jaci.2017.12.971">10.1016/j.jaci.2017.12.971</a>
15. European Medicines Agency. Excipients in Vaccines and Medicines. European Medicines Agency; 2019.
16. Shoenfeld Y, Agmon-Levin N. ASIA—autoimmune/inflammatory syndrome induced by adjuvants. <em>J Autoimmun</em>. 2011;36(1):4-8. doi:<a href="https://doi.org/10.1016/j.jaut.2010.07.003">10.1016/j.jaut.2010.07.003</a>
17. Jain A, Marshall J, Buikema A, Bancroft T, Kelly JP, Newschaffer CJ. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. <em>JAMA</em>. 2015;313(15):1534-1540. doi:<a href="https://doi.org/10.1001/jama.2015.3077">10.1001/jama.2015.3077</a>
18. Verstraeten T, Davis RL, DeStefano F. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. <em>Pediatrics</em>. 2003;112(5):1039-1048. doi:<a href="https://doi.org/10.1542/peds.112.5.1039">10.1542/peds.112.5.1039</a>
19. European Medicines Agency. COVID-19 Vaccine Safety Updates. European Medicines Agency; 2021.
20. Betsch C, Brewer NT, Brocard P, et al. Opportunities and challenges of Web 2.0 for vaccination decisions. <em>Vaccine</em>. 2012;30(25):3727-3733. doi:<a href="https://doi.org/10.1016/j.vaccine.2012.02.025">10.1016/j.vaccine.2012.02.025</a>
21. Institute of Medicine. Immunization Safety Review: Vaccines and Autoimmune Diseases. National Academies Press; 2012.
22. World Health Organization. Measles Outbreaks and Progress Toward Elimination. World Health Organization; 2019.
23. Loomba S, de Figueiredo A, Piatek SJ, de Graaf K, Larson HJ. Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. <em>Nat Hum Behav</em>. 2021;5(3):337-348. doi:<a href="https://doi.org/10.1038/s41562-021-01056-1">10.1038/s41562-021-01056-1</a>
24. Opel DJ, Heritage J, Taylor JA, et al. The architecture of provider-parent vaccine discussions at health supervision visits. <em>Pediatrics</em>. 2013; 132(6):1037-1046. doi:<a href="https://doi.org/10.1542/peds.2013-2037">10.1542/peds.2013-2037</a>
25. Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. <em>Public Health</em>. 2021;194:245-251. doi:<a href="https://doi.org/10.1016/j.puhe.2021.02.025">10.1016/j.puhe.2021.02.025</a>
26. Betsch C, Böhm R, Chapman GB. Using behavioral insights to increase vaccination policy effectiveness. <em>Policy Insights Behav Brain Sci</em>. 2023; 10(1):27-34. doi:<a href="https://doi.org/10.1177/23727322221145567">10.1177/23727322221145567</a>
27. World Health Organization. Immunization Agenda 2030: A Global Strategy to Leave No One Behind. World Health Organization; 2024.
28. Akşit SA. Aşılarla ilgili genel kurallar. <em>Klinik Gelişim</em>. 2012;25:4-11.
29. European Medicines Agency. Annual Report on Vaccine Safety Monitoring. European Medicines Agency; 2024.
Volume 5, Issue 4, 2026
Page : 115-118
_Footer